Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gisadenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 0.88 |
| ▸ | PDE6C | P51160 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gisadenafil SCHEMBL3583099 | 1.00 | PDE5A (0.88) | PDE5APDE6C | |
| Gisadenafil SCHEMBL3585141 | 0.94 | PDE5A (0.87) | PDE5APDE6C | |
| Gisadenafil SCHEMBL29379724 | 0.94 | PDE5A (1.00) | PDE5APDE6C | |
| Gisadenafil SCHEMBL120995 | 0.94 | PDE5A (1.00) | PDE5APDE6C | |
| Gisadenafil SCHEMBL6199327 | 0.90 | PDE5A (0.89) | PDE5APDE6C | |
| SCHEMBL3579657 | 0.90 | PDE5A (0.91) | PDE5APDE6C | |
| SCHEMBL3576608 | 0.90 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL4559199 | 0.89 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL3584023 | 0.89 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6767921 | 0.89 | PDE5A (0.90) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | claimed |
| US-12472186-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240207279-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11951107-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2024-04-09 | — | — | US | disclosed |
| US-11911389-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11878017-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230107723-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230071157-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11510924-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2022-11-29 | — | — | US | disclosed |
| US-11491159-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220184089-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | disclosed |
| US-11266651-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11951107-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | ADRB2, ADRA2C, ADRB1 | PDE5A 169/4885PDE6C 907/4885 |
| US-20230107723-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | PDE5A 169/4885PDE6C 907/4885 |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | PDE5A 169/4885PDE6C 907/4885 |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | PYGB, PRKG1, ACHE | PDE5A 39/4885PDE6C 382/4885 |
| US-11510924-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | ADRB2, ADRA2C, ADRB1 | PDE5A 169/4885PDE6C 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.